Steven B. Maron

Mar 21, 2024 | jnm.snmjournals.org | Samuel Cytryn |Neeta Pandit-Taskar |Melissa Lumish |Steven B. Maron

MATERIALS AND METHODSThis was a single-institution prospective pilot open-label microdose PET evaluating the PD-L1–targeting radiotracer 18F-BMS-986229 with PET imaging in 10 patients with GEC between February 3, 2020 and February 2, 2022. Ten (100%) patients had adenocarcinoma, 7 (70%) had metastatic disease, and 3 (30%) had received prior treatment at the time of PD-L1 PET imaging, including 2 with PD-1 inhibitors (Table 1). The median PD-L1 CPS was 10 (interquartile range, 5–20).